Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
about
New treatment options against gram-negative organismsReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsPhase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsComparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Ceftaroline fosamil: drug profile and clinical data.Effect of ceftaroline on normal human intestinal microflora.Ceftaroline fosamil: a brief clinical review.Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibioticsCeftaroline: a cephalosporin with expanded Gram-positive activity.Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.In vitro activity of new cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008-2011.In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolatesIn vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Current and novel antibiotics against resistant Gram-positive bacteriaCeftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unitCeftaroline in complicated skin and skin-structure infections.Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaEvaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic ModelAntimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.Molecular typing, virulence traits and antimicrobial resistance of diabetic foot staphylococciAnti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.Emerging cephalosporins.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.What is in the pipeline for Gram-negative pathogens?In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studyCurrent challenges in treating MRSA: what are the options?Activity of ceftaroline against Enterococcus faecium PBP5.Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.Newer developments in the treatment of Gram-positive infections.Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.Ceftaroline for complicated skin and skin-structure infections.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.
P2860
Q21194906-0D86FC17-0420-4698-98E3-26E54A2C741FQ24646677-D8DC7DE5-3D71-4411-A602-89D01532879FQ24672937-BD6C932B-81BA-45C9-997A-53B2546B91F5Q33613654-0AC370DB-0286-48E4-9B90-FC8DD71E5EFCQ33657212-FD8CF08F-2089-40BA-AAB2-70EDA4167D66Q33772804-7DEAAD0C-2DE5-404D-B1AE-C2BBE2FF04F0Q33826455-17ACE988-C326-481A-807B-9700670159AEQ33939080-3A065755-F5B5-4857-A3DD-47ED219911AAQ34012457-09972B43-771D-4FDF-883B-269CF1503ED3Q34016030-6ACCD706-5EBB-4014-99BB-5DD823EB0A75Q34057475-644CFF4F-163D-4F15-9093-C89251BCF503Q34363461-A7E999AD-A066-4907-A370-1978D3A3173AQ34483441-E0B72157-AEB7-4875-9E4C-46B9AC96BBF8Q35004919-1899E04F-A7F1-4179-BBD7-5451916F92E1Q35026521-97E80601-DCB7-406A-A407-0968049CADE9Q35065778-F95EA750-3BC9-4F55-B032-8EF435602C57Q35065798-1A046524-CC32-4CF0-ABD3-183BFA91884BQ35117981-5A21FB93-ECFE-4A5D-A402-1AF89A430C2EQ35191527-510287E3-2D75-4C79-BE0F-50A3A5823D97Q35427862-1FBAA9DE-6BEB-409E-857B-ADA5D37D8229Q35715381-2220830E-6321-4127-A40C-25359A375828Q35752997-5EDFA876-F111-4F5D-95F9-F62E6F1A16DDQ35859931-A601BB0D-BFDC-41EC-A4F9-520B9B86AE35Q36482771-6D7CE51F-6F46-4AAF-96FC-D815EC9993A0Q36505456-440A28ED-E4A6-4C9D-B031-F921A747138CQ36662239-F5BB67B0-0D50-4A47-92EC-7AC67A7B4FEEQ36763997-2132E43C-BADA-4D8A-912F-5F68960C9CBFQ36839703-2E6E7831-4F4C-4DAE-82E0-DAF8BA6B1D45Q36989896-BF4232CF-94BB-40F6-AEC1-60CB4E3E46E8Q37071199-83C732D6-2614-4653-9FB8-1C93F674EB3FQ37072096-0DBA4C37-A763-4B64-9F68-36679F069A21Q37077619-53D6B90E-B01F-4497-9EA4-2EF13C3BC419Q37263425-2B1E5C6D-B522-4B45-82E7-19C01C0681D7Q37291338-FAFF72DE-1C69-4ED6-BC50-464D7B05B4FFQ37335869-AA14567C-6297-4F1F-A748-3E7531C7968EQ37514259-1B1AE6DF-B9B6-40FF-8A39-AEBD2528FAD7Q37636151-2E446F45-44F7-4E74-B8E2-60ABF49F5B69Q37718228-AB0F5F25-75F9-4D1C-8C1C-0B469CE764BBQ37733561-8F5194F9-4136-4823-BBBA-351BCE1E4B45Q37785546-8D65B6D2-4846-495A-9620-02B331D1115C
P2860
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Antimicrobial activity and spe ...... ollection of clinical strains.
@ast
Antimicrobial activity and spe ...... ollection of clinical strains.
@en
type
label
Antimicrobial activity and spe ...... ollection of clinical strains.
@ast
Antimicrobial activity and spe ...... ollection of clinical strains.
@en
prefLabel
Antimicrobial activity and spe ...... ollection of clinical strains.
@ast
Antimicrobial activity and spe ...... ollection of clinical strains.
@en
P2093
P2860
P1476
Antimicrobial activity and spe ...... ollection of clinical strains.
@en
P2093
Koné Kaniga
Ronald N Jones
Thomas R Fritsche
P2860
P304
P356
10.1128/AAC.49.8.3501-3512.2005
P407
P577
2005-08-01T00:00:00Z